ES2482342A1 - TRATAMIENTO TERAPÉUTICO DE LEUCEMIAS LINFOBLÁSTICAS AGUDAS T y B Y LINFOMAS HUMANOS POR INHIBICIÓN DEL RECEPTOR DE INTERLEUQUINA-7 (IL-7R) - Google Patents

TRATAMIENTO TERAPÉUTICO DE LEUCEMIAS LINFOBLÁSTICAS AGUDAS T y B Y LINFOMAS HUMANOS POR INHIBICIÓN DEL RECEPTOR DE INTERLEUQUINA-7 (IL-7R) Download PDF

Info

Publication number
ES2482342A1
ES2482342A1 ES201232037A ES201232037A ES2482342A1 ES 2482342 A1 ES2482342 A1 ES 2482342A1 ES 201232037 A ES201232037 A ES 201232037A ES 201232037 A ES201232037 A ES 201232037A ES 2482342 A1 ES2482342 A1 ES 2482342A1
Authority
ES
Spain
Prior art keywords
human
inhibition
cells
therapeutic treatment
acute lymphoblastic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES201232037A
Other languages
English (en)
Other versions
ES2482342B1 (es
Inventor
María Luisa TORIBIO GARCÍA
Sara GONZÁLEZ GARCÍA
Marina GARCÍA PEYDRÓ
Juan ALCAIN SÁNCHEZ
Patricia FUENTES VILLAREJO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Consejo Superior de Investigaciones Cientificas CSIC
Original Assignee
Consejo Superior de Investigaciones Cientificas CSIC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consejo Superior de Investigaciones Cientificas CSIC filed Critical Consejo Superior de Investigaciones Cientificas CSIC
Priority to ES201232037A priority Critical patent/ES2482342B1/es
Priority to PCT/ES2013/070923 priority patent/WO2014102430A1/es
Publication of ES2482342A1 publication Critical patent/ES2482342A1/es
Application granted granted Critical
Publication of ES2482342B1 publication Critical patent/ES2482342B1/es
Withdrawn - After Issue legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere al tratamiento terapéutico de leucemias linfoblásticas agudas (LLA) humanas de células T y B (LLA-T y LLA-B) y linfomas humanos, por inhibición del receptor de interleuquina-7 (IL-7R) humana. Un primer aspecto de la presente invención es un agente inhibidor o bloqueante, preferentemente un anticuerpo o un fragmento del mismo, capaz de bloquear la función de la cadena α del receptor de interleuquina 7 (IL-7Rα) humano, para la prevención y/o el tratamiento de una LLA humana o de un linfoma humano. Asimismo, la presente invención hace referencia a una composición farmacéutica y a un modelo de identificación, expansión y mantenimiento in vivo de células iniciadoras de LLA-T y LLA-B primarias humanas con capacidad de iniciar el injerto de la leucemia en ratones inmunodeficientes, así como la caracterización de estas células iniciadoras de LLA-T y LLA-B como células que expresan altos niveles del IL-7R.

Description

.
ES201232037A 2012-12-27 2012-12-27 TRATAMIENTO TERAPÉUTICO DE LEUCEMIAS LINFOBLÁSTICAS AGUDAS T y B Y LINFOMAS HUMANOS POR INHIBICIÓN DEL RECEPTOR DE INTERLEUQUINA-7 (IL-7R) Withdrawn - After Issue ES2482342B1 (es)

Priority Applications (2)

Application Number Priority Date Filing Date Title
ES201232037A ES2482342B1 (es) 2012-12-27 2012-12-27 TRATAMIENTO TERAPÉUTICO DE LEUCEMIAS LINFOBLÁSTICAS AGUDAS T y B Y LINFOMAS HUMANOS POR INHIBICIÓN DEL RECEPTOR DE INTERLEUQUINA-7 (IL-7R)
PCT/ES2013/070923 WO2014102430A1 (es) 2012-12-27 2013-12-24 TRATAMIENTO TERAPÉUTICO DE LEUCEMIAS LINFOBLÁSTICAS AGUDAS T y B Y LINFOMAS HUMANOS POR INHIBICIÓN DEL RECEPTOR DE INTERLEUQUINA-7 (IL-7R)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201232037A ES2482342B1 (es) 2012-12-27 2012-12-27 TRATAMIENTO TERAPÉUTICO DE LEUCEMIAS LINFOBLÁSTICAS AGUDAS T y B Y LINFOMAS HUMANOS POR INHIBICIÓN DEL RECEPTOR DE INTERLEUQUINA-7 (IL-7R)

Publications (2)

Publication Number Publication Date
ES2482342A1 true ES2482342A1 (es) 2014-08-01
ES2482342B1 ES2482342B1 (es) 2015-07-02

Family

ID=51019933

Family Applications (1)

Application Number Title Priority Date Filing Date
ES201232037A Withdrawn - After Issue ES2482342B1 (es) 2012-12-27 2012-12-27 TRATAMIENTO TERAPÉUTICO DE LEUCEMIAS LINFOBLÁSTICAS AGUDAS T y B Y LINFOMAS HUMANOS POR INHIBICIÓN DEL RECEPTOR DE INTERLEUQUINA-7 (IL-7R)

Country Status (2)

Country Link
ES (1) ES2482342B1 (es)
WO (1) WO2014102430A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2997809A1 (en) 2015-10-07 2017-04-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Il-7r-alpha specific antibodies for treating acute lymphoblastic leukemia
EP3863671A4 (en) * 2018-10-12 2022-07-20 Jumaa-Weinacht, Hassan MONOCLONAL ANTIBODY FOR THE TREATMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA
WO2024200820A1 (en) 2023-03-30 2024-10-03 Ose Immunotherapeutics Method of synthesis of targeted lipid nanoparticle and uses thereof
EP4687991A1 (en) 2023-03-30 2026-02-11 Ose Immunotherapeutics Lipid-based nanoparticle targeted at activated immune cells for the expression of immune cell enhancing molecule and use thereof
WO2025242835A1 (en) 2024-05-22 2025-11-27 Ose Immunotherapeutics Molecules comprising masking linkers and uses thereof for the treatment of cancer
WO2026068705A1 (en) 2024-09-26 2026-04-02 Ose Immunotherapeutics Lipid-based nanoparticles comprising non-glycosylated fc domains and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006306817A (ja) * 2005-04-28 2006-11-09 Tokyo Univ Of Science プレｂ細胞急性リンパ性白血病治療剤及び治療方法、細胞増殖抑制剤、プレｂ細胞急性リンパ性白血病モデルマウス、並びにプレｂ白血病細胞株
EP2583980A1 (en) * 2011-10-19 2013-04-24 Effimune Antibodies directed against the alpha chain of IL7 receptor - their use for the preparation of drug candidates

Also Published As

Publication number Publication date
WO2014102430A1 (es) 2014-07-03
ES2482342B1 (es) 2015-07-02

Similar Documents

Publication Publication Date Title
MX2016001587A (es) Inhibidores de kdm1a para el tratamiento de enfermedades.
ES2482342A1 (es) TRATAMIENTO TERAPÉUTICO DE LEUCEMIAS LINFOBLÁSTICAS AGUDAS T y B Y LINFOMAS HUMANOS POR INHIBICIÓN DEL RECEPTOR DE INTERLEUQUINA-7 (IL-7R)
EP4424326A3 (en) Modified nk-92 cells for treating cancer
CL2019001369A1 (es) Composición farmacéutica para prevenir o tratar el cáncer de mama, incluido el polimorfo cristalino del hexoxido tetraarsenico y el método para producirlo.
MX2015013948A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
MX384315B (es) Agente para el tratamiento y/o prevención de enfermedades asociadas con anormalidades inmunes.
MX2020002150A (es) Terapia de combinación para el tratamiento del cáncer.
AR101740A1 (es) Terapia de combinación y composiciones
MX2010005718A (es) Metodo para incrementar el efecto inmunologico.
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
CL2017000317A1 (es) Terapia adjuntiva con 25-hidroxi vitamina d
MX2020004516A (es) Metodos y composiciones para la dosificacion de celulas t con receptor de antigeno quimerico alogenicas.
MX2018008078A (es) Tecnologia de sinergismo anticuerpo-farmaco para el tratamiento de enfermedades.
MX2021004819A (es) Composiciones y metodos para tratar lesiones cerebrales.
BR112014006473A2 (pt) composição e método para tratamento de uma doença autoimune
MX2020001727A (es) Terapia de combinacion.
MX385372B (es) Nuevos agentes citotóxicos que preferentemente se dirigen al factor inhibidor de leucemia (lif) para el tratamiento de malignidades y como nuevos agentes anticonceptivos
DOP2023000155A (es) Tratamiento y terapia de mantenimiento para el cáncer de vejiga con gemcitabina
BR112018003836A2 (pt) combinações de inibidor de btk para tratar mieloma múltiplo
BR112018000589A2 (pt) composição de tratamento de cabelo, método para o tratamento de cabelo e utilização de uma composição
BR112019004203A2 (pt) construto, composição farmacêutica, e, métodos para inibir angiogênese e para tratar uma doença ou enfermidade em um indivíduo distinguido por vascularização excessiva.
MX2020000636A (es) Proteinas sinteticas y usos terapeuticos de las mismas.
MX2018014129A (es) Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato.
BR112015023260A2 (pt) método de tratamento de grão com ozônio
MX2018013885A (es) Métodos de tratamiento de enfermedades asociadas con células linfoides innatas del grupo 3 (cli3).

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2482342

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20150702

FA2A Application withdrawn

Effective date: 20151102